Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Transcenta Logo
Transcenta Growth Score
46
CB Rank
21520
Heat Score
59
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture.
Founded
obfuscation
PublicPost-IPO Equity Huangpu, Shanghai, China101-250 www.transcenta.com/
Biopharma
Biotechnology
Overview

Transcenta
Total Funding
obfuscation
Growth Score
46
Heat Score
59

Total Funding
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score46
-6 pts
in past quarter
Heat Score 59
-9 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Transcenta

CB Rank
21520
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture.
Founded
obfuscation
PublicPost-IPO Equity Huangpu, Shanghai, China101-250 www.transcenta.com/
Biopharma
Biotechnology

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Series C
OBF
in
obfuscation
Series B
OBF
in
obfuscation

Key People

Details

Legal Name Transcenta Holding Ltd.
Also Known As 创胜集团
Operating Status Active
Stock Symbol  HKG:6628
Company Type For Profit
Founders  Jonathan Zhao, Xueming Qian, Yining Zhao
About the Company
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
Phone Number 0571-28279502
Contact Email media@transcenta.com
Predictions & Insights

Products & Services

Osemitamab (TST001)
A humanized monoclonal antibody targeting Claudin18.2 for treatment of gastrointestinal cancers.
TST002 (Blosozumab)
A humanized antibody targeting sclerostin for treatment of bone disorders.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
5
obfuscation
ARCH Venture Partners, Lilly Asia Ventures, Sequoia Capital, Temasek Foundation, Teng Yue PartnersPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Temasek Foundation Logo
Temasek Foundation
Yes
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
—
Temasek Foundation Logo
Temasek Foundation
Yes
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
—
Temasek Foundation Logo
Temasek Foundation
Yes
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
—
Temasek Foundation Logo
Temasek Foundation
Yes
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
—
Temasek Foundation Logo
Temasek Foundation
Yes
Post-IPO Equity - Transcenta Logo
Post-IPO Equity - Transcenta
—

Investments

Number of Acquisitions 2

Investment Breakdown

Number of Acquisitions 2
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 9 Board Members and Advisors 1 Contacts 27

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 24, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 29, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

357
64.52%
 in past month

IT Spend

$2.2MThis year, Transcenta is projected to spend $2.2M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Windows 10 Logo
Windows 10
73
Interactive Whiteboards Logo
Interactive Whiteboards
73
Conflict Resolution Logo
Conflict Resolution
73

Active Website Tech Count

32Transcenta is actively using 32 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.
Sub-Organizations
Frequently Asked Questions

Where is Transcenta's headquarters? Transcenta is located in Huangpu, Shanghai, China.Who invested in Transcenta? Transcenta has 20 investors including Temasek Foundation and  ARCH Venture Partners.When was the last funding round for Transcenta? Transcenta closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Transcenta's competitors? Alternatives and possible competitors to Transcenta may include Tempus, Avenzo Therapeutics, and  Invivyd.How much funding has Transcenta raised to date? Transcenta has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8c8a01a 1)
|